AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with stereotactic radiation therapy (sequential lung group)
Number of subjects: 106
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation to nontargeted lesions
Number of subjects: 106
Study 31658994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with stereotactic radiation therapy
Number of subjects: 106
Study 27614723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505
Study 26520894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan (60 mg, single i.m. administration)
Number of subjects: 30
Study 26520894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan (50 mg twice a day, chronic treatment for 90 days)
Number of subjects: 30
Study 26520894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single i.m. administration)
Number of subjects: 30
Study 26520894 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chronic treatment for 90 days)
Number of subjects: 30
Study 26520894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan (chronic treatment for 90 days)
Number of subjects: 30
Study 23418046 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. golimumab 100 mg at baseline and every 4 weeks through week 20 (n = 33)
Number of subjects: 49
Study 23418046 — intervention group
Group type: COMPARATOR
Intervention: i.v. golimumab 2 mg/kg at baseline and week 12 (n = 16)
Number of subjects: 49
Study 21335930 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment for hip OA
Number of subjects: 65
Study 19830964 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch adhesive system (Scotchbond Multi‐Purpose Plus, 3M ESPE)
Number of subjects: 30
Study 19830964 — intervention group
Group type: COMPARATOR
Intervention: Self-etch adhesive system (AdheSE, Ivoclar‐Vivadent)
Number of subjects: 30
Study 17090236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal packing
Number of subjects: 100
Study 17090236 — intervention group
Group type: COMPARATOR
Intervention: No pharyngeal packing
Number of subjects: 100
Study 14695722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam at a target plasma concentration of 70 ng/ml (high dose, approximately 20 mg total)
Number of subjects: 9
Study 14695722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam at a target plasma concentration of 35 ng/ml (low dose)
Number of subjects: 9
Study 14695722 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 9
Study 11721319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5-5.0 mg daily (n = 17)
Number of subjects: 34
Study 11721319 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50-100 mg daily (n = 17)
Number of subjects: 34
Study 9265098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt
Number of subjects: 120
Study 9265098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 8083009 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation exercise (Group B and C)
Number of subjects: 22
Study 8083009 — intervention group
Group type: COMPARATOR
Intervention: Rest condition (Group A)
Number of subjects: 22
Study 3033593 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(4) PFU of vaccine virus
Number of subjects: 31
Study 3033593 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(3) PFU of vaccine virus
Number of subjects: 31
Study 3033593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30474893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cistanche Yishen granules (CYG)
Number of subjects: 89
Study 30474893 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 28222810 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 14
Study 26260555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity muscles endurance exercise for 20 RM followed by cardiorespiratory endurance exercise for 24-25 minutes (type I)
Number of subjects: 212
Study 26260555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity muscles endurance exercises for 10 RM followed by cardiorespiratory endurance exercises for 26-27 minutes (type II)
Number of subjects: 212
Study 26260555 — intervention group
Group type: COMPARATOR
Intervention: Throwing a tennis ball with 10 m distance for 10 minutes (type III)
Number of subjects: 212
Study 24511715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual 200 microg of misoprostol
Number of subjects: 80
Study 24511715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21494123 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic cholecystectomy (SPLC)
Number of subjects: 43
Study 21494123 — intervention group
Group type: COMPARATOR
Intervention: Classic 4-port laparoscopic cholecystectomy (CLC)
Number of subjects: 43
Study 18647729 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech and language therapy (SLT) - language enrichment therapy, 45 min/day for 15 weekdays
Number of subjects: 125
Study 18647729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study 16409513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment for 1 hour
Number of subjects: 17
Study 16409513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment for 2 hours
Number of subjects: 17
Study 16409513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment for 3 hours
Number of subjects: 17
Study 16409513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment for 15 hours
Number of subjects: 17
Study 16409513 — intervention group
Group type: COMPARATOR
Intervention: Control group (water treatment) for 1 hour
Number of subjects: 17
Study 16409513 — intervention group
Group type: COMPARATOR
Intervention: Control group (water treatment) for 2 hours
Number of subjects: 17
Study 16409513 — intervention group
Group type: COMPARATOR
Intervention: Control group (water treatment) for 3 hours
Number of subjects: 17
Study 16409513 — intervention group
Group type: COMPARATOR
Intervention: Control group (water treatment) for 15 hours
Number of subjects: 17
Study 16409513 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca-Cola treatment overnight followed by artificial saliva for 3 minutes
Number of subjects: 17
Study 12942586 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g/day of inulin
Number of subjects: 12
Study 12942586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12973134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar instrumented fusion with posterior transpedicular screws and postoperative physiotherapy
Number of subjects: 64
Study 12973134 — intervention group
Group type: COMPARATOR
Intervention: Cognitive intervention and exercises
Number of subjects: 64
Study 10964175 — intervention group
Group type: EXPERIMENTAL
Intervention: Liaison nursing
Number of subjects: 0
Study 10964175 — intervention group
Group type: COMPARATOR
Intervention: Control (before liaison nursing)
Number of subjects: 0
Study 8846275 — intervention group
Group type: COMPARATOR
Intervention: 1% mepivacaine 7 mg.kg‐1 and normal saline 1 ml (Group 1)
Number of subjects: 42
Study 8846275 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mepivacaine 7 mg.kg‐1 plus clonidine 2 micrograms.kg‐1 and normal saline up to 1 ml (Group 2)
Number of subjects: 42
Study 8846275 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Group 1)
Number of subjects: 42
Study 1719650 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser therapy (ELT)
Number of subjects: 40
Study 1719650 — intervention group
Group type: COMPARATOR
Intervention: Palliative endoscopic perturbation (PEP)
Number of subjects: 40
Study 6206124 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation treatment
Number of subjects: 60
Study 6206124 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study 31248769 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive attention training
Number of subjects: 70
Study 31248769 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 70
Study 29211305 — intervention group
Group type: EXPERIMENTAL
Intervention: BHP+BHCC (patient bone health pamphlet and support from a bone health care coordinator)
Number of subjects: 119
Study 29211305 — intervention group
Group type: EXPERIMENTAL
Intervention: BHP+FP (patient bone health pamphlet and brief recommendations for their family physician)
Number of subjects: 119
Study 29211305 — intervention group
Group type: EXPERIMENTAL
Intervention: BHP+FP
Number of subjects: 119
Study 29211305 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study 27163943 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and etoposide alone (arm A)
Number of subjects: 152
Study 27163943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide with vismodegib (150 mg/d by mouth; arm B)
Number of subjects: 152
Study 27163943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide with cixutumumab (6 mg/kg/wk intravenously on day 1; arm C)
Number of subjects: 152
Study 27163943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CTC counts (≤100/7.5 mL) at baseline
Number of subjects: 152
Study 27163943 — intervention group
Group type: EXPERIMENTAL
Intervention: High CTC counts (>100/7.5 mL) at baseline
Number of subjects: 152
Study 25281438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked absorbable gelatin sponge
Number of subjects: 164
Study 25281438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine sponge)
Number of subjects: 164
Study 22679720 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group (CMM or acupuncture combined during rehabilitation)
Number of subjects: 236
Study 22679720 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (traditional basic drug treatment)
Number of subjects: 236
Study 20874488 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs presented in abstract form at WCE
Number of subjects: 94
Study 20874488 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs identified as RCT in the abstract title
Number of subjects: 94
Study 20874488 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding reported in RCTs
Number of subjects: 94
Study 20874488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 94
Study 20874488 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with CONSORT checklist
Number of subjects: 94
Study 18157288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellfood therapy for six months (group A)
Number of subjects: 40
Study 18157288 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three months followed by Cellfood for three months (group B)
Number of subjects: 40
Study 16266223 — intervention group
Group type: EXPERIMENTAL
Intervention: Without drains (Group I)
Number of subjects: 60
Study 16266223 — intervention group
Group type: COMPARATOR
Intervention: With two drains (Group II)
Number of subjects: 60
Study 11978721 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning health education programme
Number of subjects: 18
Study 10208507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate (oral administration)
Number of subjects: 0
Study 10208507 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (intramuscular administration)
Number of subjects: 0
Study 10208507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral and intramuscular administration)
Number of subjects: 0
Study 7603419 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk temperature at 37 degrees C (BT group)
Number of subjects: 30
Study 7603419 — intervention group
Group type: COMPARATOR
Intervention: Milk temperature at 24 degrees C (RT group)
Number of subjects: 30
Study 7603419 — intervention group
Group type: COMPARATOR
Intervention: Milk temperature at 10 degrees C (CT group)
Number of subjects: 30
Study 2192695 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction (CS) drainage
Number of subjects: 65
Study 2192695 — intervention group
Group type: COMPARATOR
Intervention: Sump (S) drainage
Number of subjects: 65
Study 483364 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg of body weight (90% coverage)
Number of subjects: 3056
Study 483364 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg of body weight (60% coverage)
Number of subjects: 3056
Study 483364 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg of body weight (40% coverage)
Number of subjects: 3056
Study 483364 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 3056
Study 483364 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 2.5 mg/kg of body weight
Number of subjects: 3056
Study 31626012 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal humeral ossification system
Number of subjects: 216
Study 31626012 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal humeral ossification system combined with Sanders hand system
Number of subjects: 216
Study 31626012 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of proximal humeral ossification, patient factors, and other classification systems
Number of subjects: 216
Study 28666680 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine by microneedle patch administered by health-care worker
Number of subjects: 100
Study 28666680 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine by intramuscular injection
Number of subjects: 100
Study 28666680 — intervention group
Group type: COMPARATOR
Intervention: Placebo by microneedle patch
Number of subjects: 100
Study 28666680 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine by self-administered microneedle patch
Number of subjects: 100
Study 25528738 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 17
Study 25528738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 23587521 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy shot without carbohydrates
Number of subjects: 94
Study 23587521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 21679319 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided skiing (28.5 days over 12 weeks)
Number of subjects: 47
Study 21679319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no skiing)
Number of subjects: 47
Study 17869497 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 5mg/kg/dose diluted in normal saline (NS) solution
Number of subjects: 60
Study 17869497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study 16849999 — intervention group
Group type: COMPARATOR
Intervention: Ventilated patients with PCP (V-PCP)
Number of subjects: 95
Study 16849999 — intervention group
Group type: COMPARATOR
Intervention: Spontaneously breathing patients with PCP (SB-PCP)
Number of subjects: 95
Study 16849999 — intervention group
Group type: COMPARATOR
Intervention: Patients with ARDS
Number of subjects: 95
Study 16849999 — intervention group
Group type: COMPARATOR
Intervention: Patients with bacterial pneumonia (PNEU)
Number of subjects: 95
Study 16849999 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers (control group)
Number of subjects: 95
Study 12616059 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized exercise program (Group E)
Number of subjects: 57
Study 12616059 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 57
Study 11819768 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 2 X 20mg, clarithromycin 2 X 500mg, and amoxicillin 2 X 1g for 7 days
Number of subjects: 167
Study 11819768 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 2 X 20mg plus placebo
Number of subjects: 167
Study 9424903 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen in ulcer and surrounding tissue
Number of subjects: 15
Study 9424903 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen polymorphism study in ulceration
Number of subjects: 15
Study 7608846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush
Number of subjects: 51
Study 7608846 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 51
Study 3366345 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms sulprostone gel
Number of subjects: 70
Study 3366345 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms sulprostone gel
Number of subjects: 70
Study 3366345 — intervention group
Group type: COMPARATOR
Intervention: Pluronic F 127 (control)
Number of subjects: 70
Study 1916580 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin-containing ointment (50,000 IU heparin/100 g)
Number of subjects: 18
Study 1916580 — intervention group
Group type: COMPARATOR
Intervention: heparin-free ointment base
Number of subjects: 18
Study 1071692 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (3 mg)
Number of subjects: 0
Study 1071692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrallazine (75 mg)
Number of subjects: 0
Study 1071692 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (1 mg)
Number of subjects: 0
Study 1071692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrallazine (20 mg)
Number of subjects: 0
Study 1071692 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 30601828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive sexual inhibition
Number of subjects: 22
Study 30601828 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational sexual inhibition
Number of subjects: 22
Study 30601828 — intervention group
Group type: COMPARATOR
Intervention: General inhibition task
Number of subjects: 22
Study 30601828 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of sexual inhibition
Number of subjects: 22
Study 30601828 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior frontal gyrus activity
Number of subjects: 22
Study 28732758 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered brief intervention with an empathic narrator
Number of subjects: 0
Study 28732758 — intervention group
Group type: COMPARATOR
Intervention: Computer-delivered brief intervention without an empathic narrator
Number of subjects: 0
Study 25388481 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated text message appointment reminders (sent at 7, 3, and 1 day before scheduled visits)
Number of subjects: 374
Study 25388481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 374
Study 24125402 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 40 mg
Number of subjects: 153
Study 24125402 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin/ezetimibe 10/10 mg
Number of subjects: 153
Study 24125402 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 153
Study 21475138 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based decision aid
Number of subjects: 152
Study 21475138 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 152
Study 20037560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinuforte, 10.0 g of amoxilav twice daily, and xylometazole (BID)
Number of subjects: 50
Study 20037560 — intervention group
Group type: COMPARATOR
Intervention: Amoxilav and xylometazole at the same doses (control group)
Number of subjects: 50
Study 20037560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinuforte
Number of subjects: 50
Study 20037560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Sinuforte)
Number of subjects: 50
Study 17578280 — intervention group
Group type: EXPERIMENTAL
Intervention: autografts of ilium (group A, n=42)
Number of subjects: 114
Study 17578280 — intervention group
Group type: EXPERIMENTAL
Intervention: interbody fusion cages (group B, n=36)
Number of subjects: 114
Study 17578280 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP/artificial bone material/cage (group C, n=36)
Number of subjects: 114
Study 17578280 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 12913187 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg/day
Number of subjects: 83
Study 12913187 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg/day
Number of subjects: 83
Study 12913187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 12913187 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline
Number of subjects: 83
Study 11006499 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol 50 microg/24 h
Number of subjects: 40
Study 11006499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9117961 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention (recommendations carried out)
Number of subjects: 167
Study 9117961 — intervention group
Group type: COMPARATOR
Intervention: No occupational therapy intervention (recommendations not carried out)
Number of subjects: 167
Study 9117961 — intervention group
Group type: COMPARATOR
Intervention: No intervention (third group)
Number of subjects: 167
Study 1500019 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of combination chemotherapy with cisplatin, vinblastine, and bleomycin followed by pelvic radiotherapy
Number of subjects: 71
Study 1500019 — intervention group
Group type: COMPARATOR
Intervention: Standard pelvic radiotherapy
Number of subjects: 71
Study 6388802 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (1250 mg/M2) and 5-fluorouracil (600 mg/M2)
Number of subjects: 49
Study 6388802 — intervention group
Group type: COMPARATOR
Intervention: Vincristine (1.5 mg/M2), doxorubicin (50 mg/M2), and cyclophosphamide (500 mg/M2)
Number of subjects: 49
Study 6388802 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CF)
Number of subjects: 49
Study 6388802 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, doxorubicin, and cyclophosphamide (VAC)
Number of subjects: 49
Study 30363041 — intervention group
Group type: EXPERIMENTAL
Intervention: RT performed 3 times per week (RT3)
Number of subjects: 27